Post-CDK4/6 Era in Breast Cancer | ESMO 2026

The treatment landscape for hormone receptor-positive, HER2-negative (HR+/HER2−) advanced breast cancer is approaching a major inflection point. Cyclin-dependent kinase (CDK) 4/6 inhibitors transformed the field by making endocrine-based combination therapy the foundation of first-line treatment. Their widespread adoption has substantially improved disease control, but it has also created a growing population of patients whose tumors progress after exposure to these agents.

This has made the post-CDK4/6 setting the next critical frontier in treatment development. ESMO 2026 is expected to provide an important assessment of this transition through late-stage studies evaluating endocrine re-treatment, pathway inhibition, CDK4/6 continuation or rechallenge, biomarker-selected therapies, and immunotherapy. Key programmes include PANKU-Breast01, VIKTORIA-1, evERA Breast Cancer, postMONARCH, CCTG/BCT MA.40/FINER, and KEYNOTE-B49.

The significance of these studies extends beyond the success or failure of any individual drug. Collectively, they may determine whether the next phase of HR+/HER2− treatment is defined by a single successor to CDK4/6 inhibition or by a more precise sequencing model in which treatment selection depends on tumor biology, molecular alterations, endocrine sensitivity, and prior therapy.

The post-CDK4/6 treatment challenge

The widespread use of CDK4/6 inhibitors is changing the characteristics of patients who enter later lines of treatment. Tumors that progress after prolonged CDK4/6 inhibition may have acquired or selected for mechanisms that permit continued proliferation despite cell-cycle suppression. However, the biological consequences of progression are not uniform.

Some tumors may remain substantially dependent on estrogen receptor signaling and retain sensitivity to alternative endocrine strategies. Others may activate downstream pathways, such as PI3K/AKT, or develop broader mechanisms of proliferative escape. As a result, progression after CDK4/6 inhibition should not be viewed as a single biological state.

This heterogeneity is increasing the importance of molecular profiling and treatment history. The clinically relevant question is no longer simply whether a patient has progressed, but how the tumor has progressed, whether endocrine dependence persists, and which resistance pathway is now dominant.

The concentration of late-stage clinical development in this setting reflects its growing importance. With CDK4/6 inhibition firmly established in the first line, the second-line and later-line settings have become the principal areas for therapeutic differentiation. The ESMO 2026 studies are particularly relevant because they address several different strategies for overcoming or redirecting treatment resistance.

Reassessing CDK4/6 inhibition

The evolution of the post-CDK4/6 landscape does not necessarily mean that CDK4/6 inhibitors will be restricted exclusively to first-line therapy. The postMONARCH programme is testing whether continued targeting of the cell-cycle pathway can retain value after prior CDK4/6 exposure.

Resistance to one CDK4/6-based combination does not automatically establish complete biological resistance to the pathway itself. A different endocrine partner, treatment context, or patient-selection strategy could preserve residual CDK4/6 dependence in a subset of patients. The key issue is whether this approach produces a meaningful clinical benefit beyond a transient progression-free survival effect.

Overall survival data from postMONARCH will therefore be particularly important. A durable survival advantage would support a more flexible role for CDK4/6 inhibition across the treatment sequence. Conversely, limited survival benefit would strengthen the rationale for moving decisively toward alternative biological pathways after progression.

Regardless of the result, postMONARCH will help define whether CDK4/6 inhibition should be viewed as a class that can be strategically reused or as a treatment whose principal value is confined to the initial disease-control phase.

Moving beyond the estrogen receptor

Another major direction is the targeting of signalling pathways downstream of the estrogen receptor. The CCTG/BCT MA.40/FINER study, evaluating fulvestrant (FASLODEX) with ipatasertib, reflects an attempt to maintain endocrine suppression while simultaneously inhibiting the AKT pathway.

This strategy is based on the premise that endocrine resistance may arise not only through changes in estrogen receptor biology but also through activation of downstream growth and survival signals. By targeting these pathways, treatment may be able to overcome resistance while preserving the benefits of endocrine therapy.

The likely importance of this approach will depend on the extent to which benefit can be linked to a defined biological subgroup. In an increasingly crowded treatment environment, modest activity in an unselected population may be less compelling than a substantial and reproducible effect in patients whose tumors demonstrate a relevant pathway alteration or dependency.

This distinction is central to the next stage of drug development. The objective is moving from broad treatment activity toward biologically informed efficacy, supported by diagnostic tests that can identify patients most likely to benefit.

Biomarkers become decisive

Studies such as evERA Breast Cancer reflect a broader change in the philosophy of HR+/HER2− drug development. The conventional HR+/HER2− classification remains clinically useful, but it does not fully describe the biological diversity that develops after multiple lines of therapy.

During treatment, tumors may acquire distinct molecular changes that alter their dependence on estrogen receptor signalling, activate alternative growth pathways, or influence sensitivity to specific agents. Consequently, the post-CDK4/6 population is likely to become increasingly segmented according to molecular and clinical characteristics.

Future treatment selection may incorporate:

• Estrogen Receptor 1 (ESR1) mutation status

• Phosphatidylinositol 3-kinase (PI3K/AKT) pathway alterations

• HER2-low or HER2-ultralow expression

• Germline or somatic alterations affecting DNA repair

• Duration of benefit from prior endocrine therapy

• Prior CDK4/6 inhibitor and endocrine partners

• Presence or absence of visceral disease

• Rate and pattern of progression

This evolution will also affect the competitive landscape. Therapies that demonstrate a clear biomarker-defined advantage may be more strongly differentiated than agents offering modest incremental benefit across a broad population. Diagnostic capability will therefore become as important as the treatment itself.

Immunotherapy enters the discussion

KEYNOTE-B49 introduces another dimension by evaluating pembrolizumab (KEYTRUDA) in combination with chemotherapy in HR+/HER2− advanced breast cancer. This represents a notable departure from the endocrine- and targeted-therapy-centered framework that has traditionally defined treatment in this subtype. 

Immunotherapy has achieved its most established role in triple-negative breast cancer, whereas HR+/HER2− tumors have generally been regarded as less immunogenic and less consistently responsive to immune checkpoint blockade. The development of a phase III immunotherapy programme in this population therefore reflects an effort to identify clinically meaningful immune-sensitive subgroups or treatment contexts.

The importance of KEYNOTE-B49 will extend beyond its individual efficacy results. A positive outcome could introduce an entirely different treatment modality into a disease landscape dominated by endocrine combinations and molecularly targeted agents.

Its eventual positioning will need to be considered carefully. The value of immunotherapy will depend not only on efficacy but also on the treatment line, chemotherapy requirement, biomarker profile, durability of benefit, immune-related toxicity, and compatibility with subsequent endocrine or targeted therapies.

From sequential treatment to treatment architecture

The studies presented at ESMO 2026 illustrate a broader change in the structure of HR+/HER2− treatment. The field is moving away from a relatively linear sequence of therapies and toward a more complex treatment architecture.

 

These approaches are not necessarily competing for an identical position. Some may be most relevant to endocrine-sensitive tumors, others to molecularly defined resistance, and others to patients requiring chemotherapy because of rapid visceral progression.

The future treatment pathway may therefore depend on matching therapy to the biological and clinical context at each progression event. A patient with an ESR1 mutation, prolonged prior endocrine benefit, and slowly progressive disease may require a fundamentally different strategy from a patient with primary endocrine resistance, aggressive visceral progression, or a targetable PI3K/AKT pathway alteration.

This shift has important commercial implications. As first-line CDK4/6 therapy becomes increasingly entrenched, the value of a new treatment will depend on its ability to occupy a clinically meaningful position after progression. Broadly active agents may have substantial utility across multiple molecular contexts, while highly targeted therapies could achieve strong differentiation in biomarker-defined populations. The likely result is a more fragmented market, but also a more sophisticated one in which efficacy, sequencing, diagnostics, tolerability, and treatment durability all contribute to clinical value.

Overall survival becomes the decisive endpoint

As patients receive multiple lines of therapy over a longer disease course, progression-free survival remains important but is no longer sufficient to establish the full value of a treatment.

The next generation of therapies will increasingly be judged by:

• Overall survival

• Durability of disease control

• Quality of life and symptom management

• Tolerability over prolonged treatment

• Preservation of subsequent treatment options

• Benefit in clinically relevant subgroups

• Feasibility of biomarker testing and treatment delivery

This is particularly important in HR+/HER2− disease, where patients may remain on systemic therapy for extended periods and receive several lines of treatment. A therapy that produces a short delay in progression but compromises quality of life or limits later options may offer less overall value than a treatment with a more durable and manageable benefit.

Overall survival analyses from studies such as postMONARCH and MA.40/FINER will therefore help determine whether these approaches can alter the long-term trajectory of the disease rather than merely postpone the next progression event.

This transition could also reshape the competitive landscape. Therapies capable of demonstrating a clear biomarker-defined advantage may achieve stronger differentiation than agents competing primarily on incremental efficacy in a broad population. The diagnostic component of treatment selection will therefore become increasingly important alongside the therapeutic component.

ESMO 2026 and the emergence of precision sequencing

The importance of ESMO 2026 may ultimately lie in the collective direction of the data rather than in a single headline result. CDK4/6 inhibitors have established a powerful therapeutic backbone for HR+/HER2− advanced breast cancer. The next challenge is to manage the growing population that progresses after this standard. The emerging strategies span endocrine re-targeting, downstream pathway inhibition, CDK4/6 continuation or rechallenge, biomarker-directed therapy, and immunotherapy.

The major change is the increasing importance of treatment selection. The post-CDK4/6 setting is becoming the point at which tumor biology, molecular alterations, prior exposure, endocrine sensitivity, disease tempo, and expected treatment benefit intersect.

This could transform the treatment pathway from a largely sequential model into a more individualized framework in which every progression event prompts reassessment of disease biology and treatment priorities.

Conclusion

ESMO 2026 could mark an important transition for HR+/HER2− advanced breast cancer. The meeting is unlikely to produce a single replacement for CDK4/6 inhibition. Instead, it may establish the foundations of a more differentiated treatment paradigm built around precision sequencing.

The next phase of progress will depend on understanding which tumors remain endocrine-sensitive, which have activated alternative pathways, which may benefit from continued cell-cycle inhibition, and which require a transition to chemotherapy or immunotherapy. The CDK4/6 era established the therapeutic backbone. The post-CDK4/6 era will be defined by how effectively clinicians and drug developers can address the resistance that follows, identify the patients most likely to benefit from each strategy, and integrate an expanding range of treatments into a coherent, patient-specific sequence.